[Effect of a new hormonal contraceptive (Neo-Eunomin) in females with androgenization symptoms].
The activity of Neo-Eunomin on androgenisation of the skin, seborrhoea, acne, alopecia and hirsutism was investigated in a long-term trial covering 165 patients over 3379 cycles. The age of the patients ranged from 19 to 47 years. The first three symptoms showed clear improvement after 6 months of treatment, and in many cases a cure was achieved after 12 months of therapy. No equally good results could at least be obtained in the treatment of hirsutism. In a further study Neo-Eunomin was compared with a contraceptive containing a nor-testosteron derivative (Conceplan 21). Neo-Eunomin showed convincingly better efficacy in the treatment of androgenisation of the skin than the preparation under comparison.
D000152:Acne Vulgaris / Q000188:drug therapy*; D000328:Adult; D000505:Alopecia / Q000188:drug therapy*; D002715:Chlormadinone Acetate / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D012628:Dermatitis, Seborrheic / Q000188:drug therapy*; D005260:Female; D006628:Hirsutism / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D009640:Norethindrone / Q000009:adverse effects / Q000627:therapeutic use*
D002715:Chlormadinone Acetate; D009640:Norethindrone
Wirkung eines neuen hormonalen Kontrazeptivums (Neo-Eunomin) bei Frauen mit Androgenisierungserscheinungen.